159 related articles for article (PubMed ID: 26535588)
61. The impact of tenofovir disoproxil fumarate on kidney function: four-year data from the HIV-infected outpatient cohort.
Monteiro N; Branco M; Peres S; Borges F; Mansinho K
J Int AIDS Soc; 2014; 17(4 Suppl 3):19565. PubMed ID: 25394072
[TBL] [Abstract][Full Text] [Related]
62. Reversibility of renal dysfunction after discontinuation of tenofovir.
Cha A; Besignano-Long AR; Rothberger N; Shah B
J Am Pharm Assoc (2003); 2016; 56(3):280-3. PubMed ID: 27067552
[TBL] [Abstract][Full Text] [Related]
63. Increased time exposure to tenofovir is associated with a greater decrease in estimated glomerular filtration rate in HIV patients with kidney function of less than 60 ml/min/1.73 m2.
Fafin C; Pugliese P; Durant J; Mondain V; Rahelinirina V; De Salvador F; Ceppi C; Perbost I; Rosenthal E; Roger PM; Cua E; Dellamonica P; Esnault V; Pradier C; Moranne O
Nephron Clin Pract; 2012; 120(4):c205-14. PubMed ID: 23037894
[TBL] [Abstract][Full Text] [Related]
64. Influence of polymorphisms of ABCB1 and ABCC2 on mRNA and protein expression in normal and cancerous kidney cortex.
Haenisch S; Zimmermann U; Dazert E; Wruck CJ; Dazert P; Siegmund W; Kroemer HK; Warzok RW; Cascorbi I
Pharmacogenomics J; 2007 Feb; 7(1):56-65. PubMed ID: 16788565
[TBL] [Abstract][Full Text] [Related]
65. High rate of reversibility of renal damage in a cohort of HIV-infected patients receiving tenofovir-containing antiretroviral therapy.
Bonjoch A; Echeverría P; Perez-Alvarez N; Puig J; Estany C; Clotet B; Negredo E
Antiviral Res; 2012 Oct; 96(1):65-9. PubMed ID: 22892171
[TBL] [Abstract][Full Text] [Related]
66. Efficacy, safety and pharmacokinetics of tenofovir disoproxil fumarate in virologic-suppressed HIV-infected children using weight-band dosing.
Aurpibul L; Cressey TR; Sricharoenchai S; Wittawatmongkol O; Sirisanthana V; Phongsamart W; Sudjaritruk T; Chokephaibulkit K
Pediatr Infect Dis J; 2015 Apr; 34(4):392-7. PubMed ID: 25760566
[TBL] [Abstract][Full Text] [Related]
67. Long-term treatment with tenofovir: prevalence of kidney tubular dysfunction and its association with tenofovir plasma concentration.
Ezinga M; Wetzels JF; Bosch ME; van der Ven AJ; Burger DM
Antivir Ther; 2014; 19(8):765-71. PubMed ID: 24584104
[TBL] [Abstract][Full Text] [Related]
68. Acute kidney injury KDIGO stage 2 to 3 in HIV-positive patients treated with cART--a case series over 11 years in a cohort of 1,153 patients.
Kurz M; Burkhalter F; Dickenmann M; Hopfer H; Mayr M; Elzi L; Battegay M
Swiss Med Wkly; 2015; 145():w14135. PubMed ID: 26023828
[TBL] [Abstract][Full Text] [Related]
69. Cumulative exposure of TDF is associated with kidney tubulopathy whether it is currently used or discontinued.
Nishijima T; Mutoh Y; Kawasaki Y; Tomonari K; Kikuchi Y; Gatanaga H; Oka S;
AIDS; 2018 Jan; 32(2):179-188. PubMed ID: 29028660
[TBL] [Abstract][Full Text] [Related]
70. Renal Function in Chinese HIV-Positive Individuals following Initiation of Antiretroviral Therapy.
Zhao Y; Zhang M; Shi CX; Zhang Y; Cai W; Zhao Q; Li Y; Li H; Liu X; Chen L; Ma Y; Zhang F; Liu Z; Wu Z
PLoS One; 2015; 10(8):e0135462. PubMed ID: 26317657
[TBL] [Abstract][Full Text] [Related]
71. Effect of TDF-containing regimens on creatinine clearance in HIV patients in Namibia with a baseline CrCl <60ml/min; findings and implications.
Kalemeera F; Godman B; Stergachis A; Rennie T
Hosp Pract (1995); 2020 Feb; 48(1):35-40. PubMed ID: 31829065
[No Abstract] [Full Text] [Related]
72. Influence of ABCC2 and ABCC4 polymorphisms on tenofovir plasma concentrations in Thai HIV-infected patients.
Rungtivasuwan K; Avihingsanon A; Thammajaruk N; Mitruk S; Burger DM; Ruxrungtham K; Punyawudho B; Pengsuparp T
Antimicrob Agents Chemother; 2015; 59(6):3240-5. PubMed ID: 25801567
[TBL] [Abstract][Full Text] [Related]
73. Subclinical tubular injury in HIV-infected individuals on antiretroviral therapy: a cross-sectional analysis.
Hall AM; Edwards SG; Lapsley M; Connolly JO; Chetty K; O'Farrell S; Unwin RJ; Williams IG
Am J Kidney Dis; 2009 Dec; 54(6):1034-42. PubMed ID: 19783343
[TBL] [Abstract][Full Text] [Related]
74. Nonalbumin proteinuria predominates in biopsy-proven tenofovir nephrotoxicity.
Sise ME; Hirsch JS; Canetta PA; Herlitz L; Mohan S
AIDS; 2015 May; 29(8):941-6. PubMed ID: 25784440
[TBL] [Abstract][Full Text] [Related]
75. Tenofovir disoproxil fumarate-associated nephrotoxicity in HIV-infected patients: a prospective controlled study.
Woratanarat K; Kanjanabuch T; Suankratay C
J Med Assoc Thai; 2013 Apr; 96(4):432-9. PubMed ID: 23691697
[TBL] [Abstract][Full Text] [Related]
76. Trend of eGFR in an Italian cohort of mother-to-child HIV-infected patients exposed to tenofovir for at least 2 years.
Grignolo S; Tatarelli P; Gustinetti G; Viazzi F; Bonino B; Maggi P; Viscoli C; Di Biagio A
Eur J Pediatr; 2015 Jun; 174(6):843-6. PubMed ID: 25511987
[TBL] [Abstract][Full Text] [Related]
77. Persistent decline in estimated but not measured glomerular filtration rate on tenofovir may reflect tubular rather than glomerular toxicity.
Vrouenraets SM; Fux CA; Wit FW; Garcia EF; Furrer H; Brinkman K; Hoek FJ; Abeling NG; Krediet RT; Reiss P;
AIDS; 2011 Nov; 25(17):2149-55. PubMed ID: 21857491
[TBL] [Abstract][Full Text] [Related]
78. Brief Report: Kidney Dysfunction Does Not Contribute Significantly to Antiretroviral Therapy Modification in Treatment-Naive PLWH Receiving Initial ART.
Eaton EF; Tamhane A; Davy-Mendez T; Moore RD; Mathews WC; Saag MS; Mugavero MJ; Wyatt CM; Gutierrez OM
J Acquir Immune Defic Syndr; 2019 May; 81(1):e6-e9. PubMed ID: 30865178
[TBL] [Abstract][Full Text] [Related]
79. Pharmacogenetics-based population pharmacokinetic analysis of tenofovir in Thai HIV-infected patients.
Rungtivasuwan K; Avihingsanon A; Thammajaruk N; Mitruk S; Burger DM; Ruxrungtham K; Sukasem C; Punyawudho B
Pharmacogenomics; 2017 Nov; 18(16):1481-1490. PubMed ID: 29061086
[TBL] [Abstract][Full Text] [Related]
80. The impact of reducing stavudine dose versus switching to tenofovir on plasma lipids, body composition and mitochondrial function in HIV-infected patients.
Milinkovic A; Martinez E; López S; de Lazzari E; Miró O; Vidal S; Blanco JL; Garrabou G; Laguno M; Arnaiz JA; Leon A; Larrousse M; Lonca M; Mallolas J; Gatell JM
Antivir Ther; 2007; 12(3):407-15. PubMed ID: 17591031
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
